ASCO 2023: Paclitaxel Tied to More Peripheral Neuropathy Than Docetaxel in Patients With Early-Stage Breast Cancer
Patient-reported and clinician-assessed outcomes through 24 weeks showed more sensory and motor neuropathy with paclitaxel
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.